Ewha Womans University Medical Center
Chemotherapy for brain tumor in the Republic of Korea costs from $1,300 to $2,700 per session. Final prices depend on the specific drug protocols, imaging requirements, and the selected medical center tier. Patients save approximately 93% compared to the US, where the average cost is $30,000. Expenses usually include the medication, specialist consultations, and administration fees.
Bookimed Expert Insight: Choosing a digitally integrated facility like Seoul National University Bundang Hospital (SNUBH) maximizes safety. Their BESTcare system specifically targets the reduction of medical errors in complex chemotherapy dosing. While Severance Hospital offers sessions starting around $1,400, the value lies in their JCI-accredited multidisciplinary approach. Patients benefit from coordinated care between world-class neurosurgeons and oncologists at Korea's top-ranked Newsweek hospitals.
| Republic of Korea | Turkey | Austria | |
| Chemotherapy for Brain Tumor | from $1,336 | from $1,000 | from $12,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Chemotherapy for Brain Tumor upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Chemotherapy for Brain Tumor and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Chemotherapy for Brain Tumor journey.
Day 1: Arrival
Day 2-3: Pre-operation
Day 4-5: Chemotherapy for Brain Tumor
Day 6: Post-operation
Week 1-2: Rehabilitation
Week 3: Return to Normal Activities
Week 4: Final Result
Please note that the timeline and process can vary depending on individual circumstances and the specifics of the brain tumor. Always consult with your healthcare team for advice tailored to your situation.
The doctor is a highly experienced Hematologist-Oncologist with over 26 years of expertise in the field. Specializing in the treatment of colon cancer, hematological oncology, myelomas, and lymphoma, the doctor is proficient in advanced procedures such as Bone Marrow Transplantation, including Alternate Donor and Mismatched Transplants.
With a strong academic background, the doctor holds an M.D. from Yonsei University College of Medicine and a Ph.D. from Sungkyunkwan University College of Medicine. The doctor is also a member of multiple professional societies and has contributed to the field through numerous paper publications.
The doctor is an expert in oncoplastic surgery and breast cancer, with extensive experience from prestigious institutions. The doctor holds an M.D. degree from Seoul National University College of Medicine and an M.S. degree in Surgery from the same institution. Additionally, the doctor earned a B.S. in biological sciences from the Korea Advanced Institute of Science and Technology (KAIST) and a Ph.D. in Surgery from Seoul National University Graduate School.
Samsung Medical Center, Asan Medical Center, and Seoul National University Hospital are the top destinations for brain tumor chemotherapy in South Korea. These JCI-accredited facilities integrate advanced systemic therapies with proton therapy and multidisciplinary neuro-oncology teams to treat over 2,000 cases annually.
Bookimed Expert Insight: While many focus on surgery, South Korea’s secret weapon is high-volume efficiency. Asan Medical Center manages 2,500+ daily inpatients, which translates to shorter chemotherapy wait times. Patients often start cycles within 2 weeks, significantly faster than in many Western healthcare systems.
Patient Consensus: Patients value the rapid MRI monitoring at Severance Hospital for catching complications early. Families also highlight the success of lower-dose regimens at SNUH for minimizing neurotoxicity during treatment.
Korean clinics follow standardized protocols using Temozolomide as the primary oral chemotherapy for high-grade gliomas. Other essential treatments include the PCV regimen (Procarbazine, Lomustine, and Vincristine) for low-grade gliomas and Bevacizumab for recurrent cases. Major centers also utilize Carmustine wafers during surgical tumor resection.
Bookimed Expert Insight: While standard protocols match international guidelines, top Seoul clinics like Asan Medical Center and Severance Hospital often use dose-intensification for younger patients. These facilities frequently combine standard chemotherapy with advanced digital imaging and AI-driven monitoring. This integration helps oncologists adjust dosage in real-time based on immediate tumor response data.
Patient Consensus: Patients value the rapid access to clinical trials and advanced genetic testing for personalized dosing. Many recommend hiring a medical translator to ensure clear communication regarding complex side effect management during long-term cycles.
South Korea reports a 5-year relative survival rate of 86.4% for all primary brain and central nervous system tumors. Malignant brain tumor survival reaches 44.1%, while non-malignant cases show 91.8%. Specialized centers like Severance Hospital and Asan Medical Center utilize advanced genomic testing to protocols.
Bookimed Expert Insight: High survival rates in Seoul stem from massive patient volumes at centers like Severance Hospital. This facility treats 1.6 million outpatients annually. This intensity allows surgeons to refine techniques for rare tumors. This experience often leads to outcomes exceeding global averages for mid-grade astrocytomas.
Patient Consensus: Patients value the routine use of MGMT and IDH testing for precise chemotherapy targeting. Many report that survival gains for low-grade tumors make navigating the long treatment cycles worthwhile.
International patients can travel home between chemotherapy sessions if they are medically stable and cleared by their South Korean oncology team. Feasibility depends on your specific treatment cycle, flight duration, and blood count stability, particularly during the 7 to 12-day post-infusion nadir period.
Bookimed Expert Insight: While Temozolomide protocols in Seoul offer some flexibility, the sheer volume of patients at centers like Asan Medical Center or Severance Hospital means follow-up slots are tight. Coordination is key because missing a 1-week post-infusion check can delay your entire regimen. We recommend booking premium economy to lie flat, as brain tumor patients face higher risks of swelling during pressure changes.
Patient Consensus: Patients emphasize carrying double the required seizure medication and securing a local neuro-oncologist at home for interim bloodwork. Managing visa extensions in Korea is also vital to avoid legal issues during multi-month treatment cycles.